You are here

Our Journey

Our Timeline 1849 - Present

We've come a long way. Journey through Pfizer's history from the first storefront to the beaches at Normandy to the New York Stock Exchange.



In 1849, cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in a red brick building in Brooklyn, NY.

Caduet® (amlodipine besylate and atorvastatin calcium), the first single pill that treats both high blood pressure and high cholesterol, is launched.

Pfizer Helpful Answers®, the pharmaceutical industry's most comprehensive prescription medicines access initiative is launched, enabling America's 45 million uninsured to obtain Pfizer medicines free or at significant savings.

The Infectious Diseases Institute, a new medical facility providing state of the art training and treatment of HIV/ADS and other infectious diseases, opens its doors on the grounds of Makerere University in Kampala, Uganda. Pfizer Inc and the Pfizer Foundation, as part of a unique public-private partnership with a number of organizations, contribute more than $15 million to support construction of the building.

Pfizer launches Lyrica® (pregabalin), the first treatment approved by the U.S. Food and Drug Administration to treat two distinct forms of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and adjunctive treatment of partial onset seizures in adults with epilepsy.

Pfizer launches Eraxis™ (anidulafungin), a new medicine to treat certain infections caused by Candida, a yeast-like fungus that can cause serious infections in hospitalized patients or patients with compromised immune systems.

Chantix™ (varenicline), a prescription medicine to help adults stop smoking, is launched by Pfizer.

In July 2006, the Pfizer Board of Directors names Jeffrey B. Kindler Chief Executive Officer. Kindler succeeds Hank McKinnell, who will remain Chairman of the Board until his retirement in February, 2007.

Pfizer launches an online site to provide up-to-date, user-friendly information on the status of its U.S. post-marketing commitments - studies conducted after a medicine receives regulatory approval and designed to provide additional information about the medicine's safety, efficacy or optimal use. This initiative is the first of its kind for a pharmaceutical company.

To help address critical gaps in malaria treatment and education, Pfizer announces the launch of Mobilize Against Malaria.

Pfizer launches a new Medicine Safety Website to help healthcare professionals and patients make better informed decisions about treatment options.

Grameen Health, an affiliate of Grameen Bank, the pioneering micro-financing organization in Bangladesh that shared the Nobel Peace Prize in 2006 for its work to alleviate poverty, partners with Pfizer to identify sustainable models for healthcare delivery in the developing world.

Pfizer launches its Global Regenerative Medicine Unit. The unit is dedicated to understanding the biology of stem cells and the opportunity these cells provide, to discover and develop a new generation of regenerative medicines that may prevent disability, repair failing organs and treat degenerative diseases.

Pfizer enters into an agreement with Medivation to develop and commercialize an investigational medicine, Dimebon, for treating Alzheimer's disease and Huntington's disease.

Learn more about the Wyeth acquisition and what it means for patients, physicians, customers and investors. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations.

Pfizer takes a new and unique approach to biomedical research, a move intended bring more innovative medicines to more patients more quickly. Specifically, Pfizer creates two distinct research organizations: The PharmaTherapeutics Research & Development Group, which focuses on discovery of small molecules and related modalities; and The BioTherapeutics Research & Development Group, which focuses on large-molecule research, including vaccines. Learn more about Pfizer's Research and Development organizations.

Pfizer launches Toviaz (fesoterodine fumarate), a prescription medicine used in adults to treat symptoms of a condition called overactive bladder.

Pfizer enters into major licensing agreements with two Indian-based pharmaceutical companies — Claris Lifesciences Ltd. and Aurobindo Pharma Ltd. — to enhance medicinal availability to underserved populations around the world and add new non-Pfizer medicines to the company's existing portfolio of established products.

Because patient participation in clinical trials is the key to progress in medical research, Pfizer enters into a collaboration with Private Access, an innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation.

Pfizer announces a diversified R&D platform named Pfizer Worldwide Research and Development, supporting excellence in small molecules, large molecules and vaccine research and development. 

As apart of the acquisition of Wyeth in 2009, Pfizer initially implemented a two-division structure for research and development (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both legacy organizations. Due to the speed and effectiveness of that integration, Pfizer progresses to this new model while maintaining the same breadth and research programs. Learn more about Pfizer's Research and Development organization.

Pfizer announces that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”), following the receipt of required regulatory clearances, including in the U.S. and the European Union.

Pfizer's subsidiary, Zoetis™ Inc., files a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal health business to Zoetis.

Pfizer announces plans to move forward to internally separate its commercial operations into three business segments, two of which will include Innovative business lines and a third which will include the Value business line. Each of the three segments will include developed markets and emerging markets. The changes are implemented in January 2014 in countries that do not require a consultation with works councils or unions, and are then implemented in countries that require consultation after the successful conclusion of those processes.